Evidence map›Paper›PMID 20806430›Full record

Trial reportWorld journal of gastroenterology2010

Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis.

Sahar K Hegazy, Mohamed M El-Bedewy

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 127 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 7 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04750135 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis

TypeinterventionalSponsorNational Hepatology & Tropical Medicine Research InstituteRan2021 to 2021Enrolled40ConditionsUlcerative Colitis, Inflammatory Bowel DiseasesArmsmetformin 500 mg TID Oral Tablet, Placebo
NCT07530575 naactive not recruitingnot on this mapstarted 2026, after this paper: background citation

Biological Effects of the Consumption of Limosilactobacillus Fermentum CRL 1446 - CONICET in Volunteers With Cardiovascular Risk Factors

TypeinterventionalSponsorPINER Pastor Manfredi WineryRan2026 to 2027Enrolled80ConditionsDisbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus)ArmsLimosilactobacillus fermentum 1446 CRL CONICET 2.20E+9 CFU, Placebo (inert excipient)
3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Trial
  15. Trial
  16. Trial
  17. Review
  18. Cheonggukjang-DerivedMetabolites · 2026
    Article
  19. Review
  20. Protective Effects ofFoods (Basel, Switzerland) · 2026
    Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sahar K HegazyDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta 8130, Egypt. saharhegazy96@yahoo.co.uk
Mohamed M El-Bedewy
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo demonstrate the therapeutic effect of probiotics in patients with ulcerative colitis (UC), and their effect on inflammatory mediators and nuclear factor (NF)-kappaB activation in these patients.

methodsThirty patients with mild to moderate UC were randomly classified into two groups: sulfasalazine group, who received sulfasalazine 2400 mg/d; and probiotic group, who received sulfasalazine 2400 mg/d with probiotic. The patients were investigated before and after 8 wk of treatment with probiotic (Lactobacillus delbruekii and Lactobacillus fermentum). Colonic activity of myeloperoxidase (MPO) was assayed with UV spectrophotometry, the colonic content of interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay (ELISA), fecal calprotectin was determined by ELISA, and expression of NF-kappaB p65 and tumor necrosis factor (TNF)-alpha proteins in colonic tissue was identified by immunohistochemistry and reverse transcription polymerase chain reaction, respectively.

resultsAt the start of the study, colonic mucosal injury and inflammation were demonstrated in UC patients by hematoxylin and eosin staining, and an increase in colonic MPO activity, fecal calprotectin, and expression of colonic TNF-alpha and NF-kappaB p65 proteins. The use of probiotic for 8 wk significantly ameliorated the inflammation by decreasing the colonic concentration of IL-6, expression of TNF-alpha and NF-kappaB p65, leukocyte recruitment, as demonstrated by a decrease in colonic MPO activity, and the level of fecal calprotectin compared to sulfasalazine group and the control group (P < 0.05).

conclusionOral supplementation with probiotics could be helpful in maintaining remission and preventing relapse of UC.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeFecesFemaleHumansInterleukin-6Intestinal MucosaLactobacillus delbrueckiiLeukocyte L1 Antigen ComplexLimosilactobacillus fermentumMaleMiddle AgedNF-kappa BPeroxidaseProbioticsSulfasalazineAnti-Inflammatory Agents, Non-SteroidalInterleukin-6Leukocyte L1 Antigen ComplexNF-kappa BPeroxidaseSulfasalazineTumor Necrosis Factor-alpha

Identifiers

PMID20806430
PMCPMC2932917
OpenAlexW1984280786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.